Table 2.
Comparison of clinical characteristics and outcomes in ENKTL cohorts from North America, Europe, and Asia
| Lee et al. (N=262) |
MDACC (N=73) |
MSKCC (N=43) |
Canada (N=34) |
Italian (N=26) |
France 1 (N=13) |
OSU 2 (N=7) |
|
|---|---|---|---|---|---|---|---|
| Med Age (range) | 79% ≥ 59 | 46 (18–88) | 53 (24–81) | 53 (23–89) | 51 (20–80) | 62 (15–86) | 48 (32–74) |
| Race (%) | |||||||
| White | 43 (59) | 32 (74) | 16 (47) | 26 (100) | 4 (31) | 5 (71) | |
| Hispanic | 18 (24) | 1 (3) | |||||
| Asian | 262 (100) 6 | 8 (11) | 10 (23) | 16 (47) | 5 (38) | ||
| Black/Other | 4 (6) | 1 (3) | 4 (38) | 2 (29) | |||
| Gender (M:F) | 13:07 | 49:24:00 | 24:19:00 | 2:01 | 19:07 | 9:04 | 2:05 |
| Type (%) | |||||||
| Nasal | 222 (85) | 63 (86) | 28 (65) | 34 (100) | 23 (88) | 13 (100) | 5 (71) |
| Extranasal | 40 (15) | 10 (14) | 15 (35) | 3 (12) | 2 (29) | ||
| Stage (%) | |||||||
| I/II | 200 (76) | 44 (65) | 26 (61) | 28 (82) | 18 (69) | 13 (100) | 5 (71) |
| III/IV | 62 (24) | 24 (35) | 17 (39) | 6 (18) | 8 (31) | 2 (29) | |
| Treatment (%) | |||||||
| CT | 119 (46) | 14 (22) | 14 | 9 (34) | 13 (100) | 5 (71) | |
| Local Tx | 18 (7) | 8 (13) | 2 RT | 2 | 1 (4) 3 | ||
| CT+Local Tx | 120 (46) | 42 (66) | 24 | 32 | 16 (62) 4 | 2 (29) | |
| Outcomes | 5 yr PFS 60% 5 | Med PFS 3yrs | 2 yr PFS 40% | 2 yr PFS 18% | Med PFS 14 mos 5 | 2 yr PFS 72% | 83% CR |
| 5 yr OS 50% | Med OS 4.2yrs | 2 yr OS 60% | 2 yr OS 39% | Med OS 9 mos | 2 yr OS 90% | (5 CR, 1 PD, 1 unk) | |
Med=Median; MDACC=MD Anderson Cancer Center; MSKCC=Memorial Sloan Kettering Cancer Center; OSU=Ohio State University; unk=unknown; CT=chemotherapy; Local Tx=local treatment with either RT or Sx; Sx=surgery; RT=radiation; PFS=progression free survival; OS=overall survival; yr=year; mos=months;
All treated with concurrent chemoradiotherapy with ESHAP;
Two treated with asparginase alone, remaining patients treated with mSMILE;
One treated with Sx alone.
Of the 16 treated with CT+ local Tx, 14 treated with RT alone & 2 treated with RT + Sx;
PFS calculated for responders only;
All patients accrued from tertiary hospitals in Korea. Race/ethnicity not reported in manuscript.